12 August 2020 VACCIBODY AND NEKTAR THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1/2A STUDY ARM EVALUATING VB10.NEO IN COMBINATION WITH BEMPEGALDESLEUKIN First patient dosed in VB N-01 study arm with VB10.NEO plus Bempegaldesleukin (NKTR-214) Download Go back
